Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U... Show more
The 50-day moving average for HROW moved above the 200-day moving average on August 12, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
HROW moved above its 50-day moving average on August 04, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 210 cases where HROW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for HROW moved out of overbought territory on August 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where HROW's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HROW as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HROW turned negative on September 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HROW broke above its upper Bollinger Band on August 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HROW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.855) is normal, around the industry mean (16.591). P/E Ratio (0.000) is within average values for comparable stocks, (73.712). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). HROW has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (5.910) is also within normal values, averaging (42.700).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a pharmaceutical company
Industry PharmaceuticalsGeneric
A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.
Ticker / NAME | Correlation To HROW | 1D Price Change % | ||
---|---|---|---|---|
HROW | 100% | -1.01% | ||
AQST - HROW | 34% Loosely correlated | +3.00% | ||
OGI - HROW | 34% Loosely correlated | -1.52% | ||
TKNO - HROW | 32% Poorly correlated | +0.59% | ||
AMRX - HROW | 32% Poorly correlated | -0.42% | ||
VTRS - HROW | 30% Poorly correlated | -0.09% | ||
More |
Ticker / NAME | Correlation To HROW | 1D Price Change % |
---|---|---|
HROW | 100% | -1.01% |
Pharmaceuticals: Generic industry (223 stocks) | 12% Poorly correlated | -0.32% |